1. 1- Arora S, Dhull VS, Karunanithi S, Parida GK, Sharma A, Shamim S. 99m Tc-MDP SPECT/CT as the one-stop imaging modality for the diagnosis of early setting of Kienbock's disease. Rev Esp Med Nucl Imagen Mol 2015; 34(3): 185-7.
2. 2- Zhao Z, Li L, Li F, Zhao L. Single photon emission computed tomography/spiral computed tomography fusion imaging for the diagnosis of bone metastasis in patients with known cancer. Skeletal Radiol 2010; 39(2): 147-53.
3. 3- Krol A. Nuclear Medicine Physics: The Basics. 5th ed.Radiology; 1992;208(1):142.
4. 4- Brown ML, Collier BD Jr, Fogelman I. Bone scintigraphy: part 1. oncology and infection. J Nucl Med 1993; 34(12): 2236-40.
5. 5- Min JW, Um SW, Yim JJ, Yoo CG, Han SK, Shim YS, Kim YW. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci 2009; 24(2): 275-80.
6. 6- Şahin E, Elboğa U, Kalender E. An Incidental Finding of Extraosseous Uptake in Technetium 99m Methylene Diphosphonate Bone Scintigraphy: Uterine Leiomyoma. J Med Imaging Radiat Sci 2014; 45(2): 141-3.
7. 7- Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 2011; 21(12): 2604-17.
8. 8- Helal N. Patient organs dose calculations in nuclear medicine. Int J Res Rev Appl Sci 2012; 11(1): 153-61.
9. 9- Davis MA, Jones AG. Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging. Semin Nucl Med 1976: 6(1): 19-31.
10. 10- Khan AH, Yusof CN, Ahmad A, Sulaiman SA. Bone Syntigraphy with^ sup 99m^ Tc-MDP in Breast Cancer Patient. Int J Pharm Sci Res 2012; 4(12): 2015-17.
11. 11- Schaefer C, Meister R, Wentzeck R, Weber-Schoendorfer C. Fetal outcome after technetium scintigraphy in early pregnancy. Reprod Toxicol 2009; 28(2): 161-6.
12. 12- Stabin MG. Uncertainties in internal dose calculations for radiopharmaceuticals. J Nucl Med 2008; 49(5): 853-60.
13. 13- Amato E, Campennì A, Herberg A, Minutoli F, Baldari S. Internal Radiation Dosimetry: Models and Applications. 12 Chapters on Nuclear Medicine: InTech;2011.
14. 14- Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37(3): 538-46.
15. 15- Fisher DR, Shen S, Meredith RF. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In-and 90Y-ibritumomab tiuxetan. J Nucl Med 2009; 50(4): 644-52.
16. 16- Siegel JA, Thomas SR, Stubbs JB, Stabin MG. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999; 40(2): 37S-61S.
19. 17- Zanzonico P. Nuclear Medicine Radiation Dosimetry, Advanced Theoretical Principles.: Medical physics.2011; 38(1):549.
20. 18- Bambara LT, Kyere AK, Hasford F, Sosu EK, Wilson IK. Estimation of kidney and bladder radionuclide activity for patients undergoing bone scan. J Radiat Res Appl Sci 2015; 8(3): 317-22.
24. 19- Marcatili S, Villoing D, Mauxion T, McParland B, Bardiès M. Model-based versus specific dosimetry in diagnostic context: Comparison of three dosimetric approaches. Med Phy 2015; 42(3): 1288-96.
26.